publication

Muscle mass loss and dose limiting toxicities in mCRC patients

Title: Skeletal muscle mass loss and dose limiting toxicities in metastatic colorectal cancer patients

Authors: SA Kurk MDAB, PHM Peeters MD PhDB, RK Stellato MSC, B Dorresteijn PhDD, PA de Jong MD PhDE, M Jourdan PhDF, G-JM Creemers MD PhDG, FLG Erdkamp MD PhDH, FE de Jongh MD PhDI, PAM Kint MDJ, LHJ Simkens MDK, BC Tanis MD PhDL, MLR Tjin-A-Ton MDM, A Van Der Velden MD PhDN, CJA Punt MD PhDO, M Koopman MD PhDP*, AM May PhDQ*
Published: 2019
Journal:

Journal of Cachexia, Sarcopenia and Muscle

The study investigated and reported the association of sarcopenia and/or muscle loss of mCRC patients during palliative systemic treatment with an increased risk of DLTs. BMI was not associated with DLTs and could not be used to detect sarcopenia or SMI loss.

Please click here for the full publication.

Citation: Kurk, S., Peeters, P., Stellato, R., Dorresteijn, B., Jong, P., Jourdan, M., Creemers, G.‐J., Erdkamp, F., Jongh, F., Kint, P., Simkens, L., Tanis, B., Tjin‐A‐Ton, M., Van Der Velden, A., Punt, C., Koopman, M., and May, A. ( 2019) Skeletal muscle mass loss and dose‐limiting toxicities in metastatic colorectal cancer patients, Journal of Cachexia, Sarcopenia and Muscle, doi: https://doi.org/10.1002/jcsm.12436.